(S (NP (NN Combination) (NN therapy)) (VP (VBZ has) (VP (VBN shown) (S (VP (TO to) (VP (VB improve) (NP (JJ therapeutic) (NN efficacy)) (SBAR (IN while) (S (VP (VBG reducing) (NP (JJ side) (NNS effects)))))))))) (. .))
(S (ADVP (RB Importantly)) (, ,) (NP (PRP it)) (VP (VBZ has) (VP (VBN become) (NP (NP (DT an) (JJ indispensable) (NN strategy)) (SBAR (S (VP (TO to) (VP (VB overcome) (NP (NP (NN resistance)) (PP (IN in) (NP (NP (NNS antibiotics)) (, ,) (NP (NNS anti-microbials)) (, ,) (CC and) (NP (JJ anti-cancer) (NNS drugs)))))))))))) (. .))
(S (S (VP (VBG Facing) (NP (NP (JJ enormous) (NN chemical) (NN space)) (CC and) (NP (NP (JJ unclear) (NN design) (NNS principles)) (PP (IN for) (NP (JJ small-molecule) (NNS combinations))))))) (, ,) (NP (DT the) (JJ computational) (NN drug-combination) (NN design)) (VP (VBZ has) (RB not) (VP (VBN seen) (NP (NP (JJ generative) (NNS models)) (SBAR (S (VP (TO to) (VP (VB meet) (NP (PRP$ its) (JJ potential) (S (VP (TO to) (VP (VB accelerate) (NP (JJ resistance-overcoming) (NN drug) (NN combination) (NN discovery))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP have) (VP (VBN developed) (NP (NP (DT the) (JJ first) (JJ deep) (NN generative) (NN model)) (PP (IN for) (NP (NN drug) (NN combination) (NN design)))) (, ,) (PP (IN by) (S (VP (VP (ADVP (RB jointly)) (VBG embedding) (NP (JJ graph-structured) (NN domain) (NN knowledge))) (CC and) (VP (ADVP (RB iteratively)) (VBG training) (NP (DT a) (ADJP (JJ reinforcement) (JJ learning-based)) (NN chemical) (NN graph-set) (NN designer)))))))) (. .))
(S (ADVP (RB First)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN developed) (NP (NP (NNP Hierarchical) (NNP Variational) (NNP Graph) (NNP Auto-Encoders)) (PRN (-LRB- -LRB-) (NP (NNP HVGAE)) (-RRB- -RRB-)) (VP (VBD trained) (ADVP (JJ end-to-end)) (S (VP (TO to) (VP (ADVP (RB jointly)) (VB embed) (NP (ADJP (JJ gene-gene) (, ,) (JJ gene-disease) (, ,) (CC and) (JJ disease-disease)) (NNS networks))))))))) (. .))
(S (NP (NNP Novel) (JJ attentional) (NN pooling)) (VP (VBZ is) (VP (VBN introduced) (ADVP (RB here)) (PP (IN for) (S (VP (VBG learning) (NP (NNS disease-representations)) (PP (IN from) (NP (NP (VBN associated) (NNS genes) (POS â€º)) (NNS representations)))))))) (. .))
(S (ADVP (JJ Second)) (, ,) (S (VP (VBG targeting) (NP (NNS diseases)) (PP (IN in) (NP (JJ learned) (NNS representations))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VP (VBN recast) (NP (DT the) (NN drug-combination) (NN design) (NN problem)) (PP (IN as) (NP (JJ graph-set) (NN generation)))) (CC and) (VP (VBD developed) (NP (NP (DT a) (JJ deep) (JJ learning-based) (NN model)) (PP (IN with) (NP (JJ novel) (NNS rewards))))))) (. .))
(S (ADVP (RB Specifically)) (, ,) (PP (IN besides) (NP (JJ chemical) (NN validity) (NNS rewards))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN introduced) (NP (NP (DT a) (JJ novel) (JJ generative) (JJ adversarial) (NN award)) (, ,) (VP (VBG being) (VP (VBN generalized) (S (NP (JJ sliced) (NNP Wasserstein)))))) (, ,) (PP (IN for) (NP (NP (ADJP (RB chemically) (JJ diverse)) (NNS molecules)) (PP (IN with) (NP (NP (NNS distributions)) (ADJP (JJ similar) (PP (TO to) (NP (VB known) (NNS drugs)))))))))) (. .))
(S (NP (PRP We)) (VP (VBP have) (ADVP (RB also)) (VP (VBN designed) (NP (NP (DT a) (NN network) (JJ principle-based) (NN reward)) (PP (IN for) (NP (NN drug) (NNS combinations)))))) (. .))
(S (NP (JJ Numerical) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (, ,) (S (PP (VBN compared) (PP (TO to) (NP (VB graph) (VBG embedding) (NNS methods)))) (, ,) (NP (NNP HVGAE)) (VP (VBZ learns) (NP (ADJP (RBR more) (JJ informative) (CC and) (JJ generalizable)) (NN disease) (NNS representations)))))) (. .))
(S (NP (NP (NNP Case) (NNS studies)) (PP (IN on) (NP (CD four) (NNS diseases)))) (VP (VBP show) (SBAR (IN that) (S (NP (JJ network-principled) (NN drug) (NNS combinations)) (VP (VBP tend) (S (VP (TO to) (VP (VB have) (NP (JJ low) (NN toxicity))))))))) (. .))
(S (NP (DT The) (JJ generated) (NN drug) (NNS combinations)) (VP (VP (ADVP (RB collectively)) (VBP cover) (NP (NP (DT the) (NN disease) (NN module)) (ADJP (JJ similar) (PP (TO to) (NP (JJ FDA-approved) (NN drug) (NNS combinations)))))) (CC and) (VP (MD could) (ADVP (RB potentially)) (VP (VB suggest) (NP (JJ novel) (JJ systems-pharmacology) (NNS strategies))))) (. .))
